BRCAm n = 15 | BRCAwt n = 25 | p-Value* | Untested n = 128 | p-Value** | |
---|---|---|---|---|---|
Year of Ovarian Cancer Diagnosis | |||||
Median (IQR) | 2007 (2004–2009) | 2008 (2005–2010) | 0.305 | 2004 (2000–2007) | 0.027 |
Year of PSR Diagnosis | |||||
Median (IQR) | 2008 (2006–2011) | 2010 (2008–2012) | 0.201 | 2006 (2003–2009) | 0.043 |
Age at Recurrence, Years | |||||
Median age (IQR) | 58 (48–64) | 57 (50–63) | 0.900 | 63 (54–71) | 0.052 |
Mean age ± SD | 56 ± 11.0 | 56 ± 9.7 | 0.903 | 63 ± 12.7 | 0.033 |
Age group | |||||
<60 years | 8 (53.3 %) | 15 (60.0 %) | 0.231 | 50 (39.1 %) | 0.039 |
60–74 years | 5 (33.3 %) | 10 (40.0 %) | 55 (43.0 %) | ||
≥75 years | 2 (13.3 %) | 0 | 23 (18.0 %) | ||
Ethnicity | |||||
White | 8 (53 %) | 18 (72 %) | 0.138 | 84 (66 %) | 0.372 |
Hispanic | 2 (13 %) | 0 (0 %) | 7 (5 %) | ||
Other | 0 (0 %) | 2 (8 %) | 6 (5 %) | ||
Unknown | 5 (33 %) | 5 (20 %) | 31 (24 %) | ||
Family History of Hereditary Breast or Ovarian Cancer | |||||
No family history | 0 (0 %) | 14 (56 %) | <0.001 | 103 (80 %) | <0.001 |
Familial risk | 15 (100 %) | 11 (44 %) | 25 (20 %) | ||
Personal History of Breast Cancer | |||||
No history | 10 (67 %) | 22 (88 %) | 0.126 | 121 (95 %) | 0.003 |
History of breast cancer | 5 (33 %) | 3 (12 %) | 7 (5 %) | ||
Stage at Ovarian Cancer Diagnosis | |||||
≤2 | 2 (13.3 %) | 5 (20 %) | 0.900 | 21 (16.4 %) | 0.917 |
≥3 | 10 (66.7 %) | 15 (60 %) | 87 (68.0 %) | ||
Unknown | 3 (20 %) | 5 (20 %) | 20 (15.6 %) | ||
Pathology | |||||
Serous | 10 (66.7 %) | 18 (72 %) | 0.910 | 77 (60.2 %) | 0.759 |
Adenocarcinoma | 1 (6.7 %) | 1 (4 %) | 14 (10.9 %) | ||
Endometrioid | 0 | 1 (4 %) | 11 (8.6 %) | ||
Other | 4 (26.7 %) | 5 (20 %) | 26 (20.3 %) | ||
Tumor Histologic Grade at Ovarian Cancer Diagnosis | |||||
1 and 2 | 2 (13.3 %) | 3 (12 %) | 0.847 | 15 (11.7 %) | 0.855 |
3 | 7 (46.7 %) | 8 (32 %) | 68 (53.1 %) | ||
4 | 2 (13.3 %) | 5 (20 %) | 12 (9.4 %) | ||
Unknown | 4 (26.7 %) | 9 (36 %) | 33 (25.8 %) | ||
Primary Tumor Site | |||||
Ovary | 12 (80 %) | 20 (80 %) | 0.574 | 113 (88.3 %) | 0.363 |
Peritoneum | 3 (20 %) | 3 (12 %) | 11 (8.6 %) | ||
Fallopian tube | 0 (0 %) | 2 (8 %) | 4 (3.1 %) | ||
Ca-125 at Recurrence (Highest Value ±30 days), U/mL | |||||
Median Ca-125 (IQR) | 195 (82–274) | 49.5 (36.5–178) | 0.218 | 90 (34–343) | 0.549 |
ECOG score | |||||
Median ECOG (IQR) | 1 (0–1) | 0 (0–1) | 0.457 | 1 (0–1) | 0.634 |
ECOG group | |||||
≤2 | 6 (40 %) | 14 (56 %) | 0.514 | 34 (26.6 %) | 0.490 |
≥3 | 0 | 0 | 2 (1.6 %) | ||
Unknown | 9 (60 %) | 11 (44 %) | 92 (71.9 %) | ||
Initial Treatment at Ovarian Cancer Diagnosis | |||||
Chemotherapy | 7 (46.7 %) | 12 (48 %) | 0.547 | 50 (39.1 %) | 0.504 |
Neoadjuvant chemotherapy | 4 (26.7 %) | 3 (12 %) | 11 (8.6 %) | ||
Radiation therapy | 0 | 0 | 2 (1.6 %) | ||
Primary debulking or cytoreductive surgery | 9 (60 %) | 23 (92 %) | 110 (86 %) | ||
Missing | 0 | 0 | 1 (0.8 %) | ||
Duration of Follow-up, Days | |||||
Median (IQR) | 1064 (656–2231) | 981.5 (434–1546) | 0.419 | 490 (219–1015) | 0.005 |